GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. Wen, P. Y., Mellinghoff, I. K., Buxton, M., Cavenee, W. K., Colman, H., De Groot, J., Ellingson, B. M., Gordon, G. B., Khasraw, M., Lassman, A. B., Lim, M., Perry, J. R., Tanner, K., Weller, M., Yung, W., Cloughesy, T., GBM AGILE Investigators LIPPINCOTT WILLIAMS & WILKINS. 2021

View details for DOI 10.1200/JCO.2021.39.15_suppl.TPS2074

View details for Web of Science ID 000708120306194